XLO
XLO
NASDAQ · Biotechnology

Xilio Therapeutics Inc

$9.05
+0.01 (+0.11%)
Financial Highlights (FY 2026)
Revenue
34.49M
Net Income
-27,609,276
Gross Margin
—
Profit Margin
-80.1%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — 31.0% 31.0% 31.0%
Operating Margin -95.9% -12.7% -12.5% -13.4%
Profit Margin -80.1% -10.6% -13.0% -12.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 34.49M 12.59M 12.91M 9.78M
Gross Profit — 3.90M 4.00M 3.03M
Operating Income -33,081,091 -1,593,118 -1,614,371 -1,306,842
Net Income -27,609,276 -1,338,243 -1,683,285 -1,199,258
Gross Margin — 31.0% 31.0% 31.0%
Operating Margin -95.9% -12.7% -12.5% -13.4%
Profit Margin -80.1% -10.6% -13.0% -12.3%
Rev Growth — -1.9% -7.4% -8.7%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 16.15M 16.94M 14.90M
Total Equity — 15.37M 18.19M 17.29M
D/E Ratio — 1.05 0.93 0.86
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -31,868,512 -1,969,871 -1,762,148 -1,377,431
Free Cash Flow — -1,414,748 -1,276,245 -1,101,740